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Betacellulin Regulates Hair Follicle Development
and Hair Cycle Induction and Enhances Angiogenesis
in Wounded Skin
Marlon R. Schneider1, Maria Antsiferova2, Laurence Feldmeyer2, Maik Dahlhoff1, Philippe Bugnon2,
Sybille Hasse3, Ralf Paus3, Eckhard Wolf1,4 and Sabine Werner2,4
Betacellulin (BTC) belongs to the EGF family, whose members play important roles in skin morphogenesis,
homeostasis, and repair. However, the role of BTC in skin biology is still unknown. We employed transgenic
mice overexpressing BTC ubiquitously to study its role in skin physiology. Immunohistochemistry revealed
increased levels of BTC especially in the hair follicles and in the epidermis of transgenic animals. Expression of
key markers of epithelial differentiation was unaltered, but keratinocyte proliferation was significantly
increased. At post-natal day 1 (P1), transgenic mice displayed a significant retardation of hair follicle
morphogenesis. At P17, when most follicles in control mice had initiated hair follicle cycling and had already
entered into their first late catagen or telogen phase, all follicles of transgenic mice were still at the mid- to late
catagen phases, indicating retarded initiation of hair follicle cycling. Healing of full-thickness excisional wounds
and bursting strength of incisional wounds were similar in control and transgenic mice. However, an increase in
the area covered by blood vessels at the wound site was detected in transgenic animals. These results provide
evidence for a role of BTC in the regulation of epidermal homeostasis, hair follicle morphogenesis and cycling,
and wound angiogenesis.
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INTRODUCTION
Betacellulin (BTC) is one of seven peptide growth factors,
which can directly bind and activate the EGFR (ErbB1). The
other known EGFR ligands are EGF, amphiregulin (AREG),
heparin-binding EGF-like growth factor (HBEGF), transform-
ing growth factor-alpha (TGF-a), epiregulin, and epigen
(Harris et al., 2003). This list is most likely complete, since
a genome-wide search employing algorithms based on
genomic and cDNA structures failed to identify further
potential EGFR ligands (Kochupurakkal et al., 2005). EGFR
ligands are initially synthesized as membrane-bound pre-
cursors that can be cleaved (shedded) extracellularly to
release the mature, circulating form. The major effectors of
this post-translational modification belong to the ADAM
family of proteases (Sahin et al., 2004). Interestingly, the
precursor form exerts biological activity by stimulating
adjacent cells via cell–cell contacts, a mechanism termed
juxtacrine action (Brachmann et al., 1989; Wong et al., 1989;
Goishi et al., 1995; Higashiyama et al., 1995).
The EGFR (ErbB1) is the prototype of a family of four
tyrosine kinase receptors, which also includes ErbB2 (neu),
ErbB3, and ErbB4. Ligand binding induces the formation of
homo- or heterodimers and activation of the kinase domains
(Yarden and Sliwkowski, 2001; Holbro and Hynes, 2004; Citri
and Yarden, 2006). BTC, HBEGF, and epiregulin can directly
activate ErbB4 in addition to ErbB1. Reflecting the essential
role of ErbBs during mammalian development, complete loss
of EGFR activity in knockout mice results in death either at an
embryonic stage, in the perinatal period, or after a few weeks
of post-natal life, depending on the genetic background
(Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill
et al., 1995). Knockout mice lacking ErbB2, -3, or -4 die
inevitably during embryonic development (Gassmann et al.,
1995; Lee et al., 1995; Riethmacher et al., 1997).
There is abundant evidence that normal development and
homeostasis of the skin and its appendages, specifically of
hair follicles, depend on the correct expression and activity of
the EGFR and its ligands. EGFR, ErbB2, and ErbB3 are
expressed in normal human skin (Press et al., 1990; Prigent
et al., 1992; Hudson and McCawley, 1998; De Potter
et al., 2001; Stoll et al., 2001; Piepkorn et al., 2003) and
in the HaCaT keratinocyte line (Marques et al., 1999).
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Overexpression of the EGFR has been detected in epithelial
squamous cell carcinomas (Yamamoto et al., 1986; Derynck
et al., 1987) and in psoriasis (King et al., 1990; Nanney et al.,
1992), and substantial evidence implicates ErbB signaling as
a major component in the pathogenesis of non-melanoma
skin cancer (Hansen et al., 2000; Sibilia et al., 2000). Finally,
overexpression of multiple EGFR ligands occurs in psoriatic
epidermis (Elder et al., 1989; Piepkorn, 1996; Piepkorn et al.,
1998; Stoll and Elder, 1998).
EGFR ligands are autocrine-acting growth factors for
keratinocytes, playing a central role in controlling prolifera-
tion of these cells (Coffey et al., 1987; Cook et al., 1991;
Hashimoto et al., 1994; Stoll et al., 1997; Piepkorn et al.,
1998; Shirakata et al., 2000). This activity can be inhibited by
blocking the EGFR kinase activity (Piepkorn et al., 1994; Peus
et al., 1997). Interestingly, ectodomain shedding of EGFR
ligands, particularly of HBEGF, was demonstrated to be
essential for keratinocyte migration and efficient healing of
skin wounds (Tokumaru et al., 2000).
Genetically modified mouse models have been seminal in
the study of the role of EGFR and its ligands in the skin and its
appendages. For instance, the genetic basis of the phenotype
of waved mice (animals displaying waved hairs and curly
vibrissae known to researchers since the late 1930s) was
identified as a point mutation in the tgf-a (wa1) or the egfr
(wa2) genes (Luetteke et al., 1993, 1994; Mann et al., 1993).
Although no obvious skin phenotype is present in egfrþ /
mice, further decreases in EGFR activity by expression of a
dominant-negative EGFR mutant (Murillas et al., 1995), or the
antimorphic wa5 allele (Lee et al., 2004), result in the
appearance of the waved phenotype. Surviving egfr-knockout
mice display a severe phenotype of epidermal atrophy and
extremely low rates of keratinocyte proliferation (Miettinen
et al., 1995; Sibilia and Wagner, 1995; Threadgill et al.,
1995).
Except for TGF-a (Luetteke et al., 1993; Mann et al., 1993;
Kim et al., 2001) and HBEGF (Shirakata et al., 2005), loss of
other EGFR ligands failed to reveal a skin phenotype. The
opposite approach, however, the overexpression of the
growth factor using epithelial-specific or ubiquitous regula-
tory sequences, resulted in readily observable phenotypes,
including wrinkled skin, alopecia and papillomas for
TGF-a (Vassar and Fuchs, 1991; Dominey et al., 1993), a
psoriasis-like phenotype for AREG (Cook et al., 1997,
2004), or arrested hair follicle development for EGF (Mak
and Chan, 2003).
Although BTC is expressed in the skin, its role in skin
biology is largely unknown. In human skin, BTC expression
appears to be restricted to suprabasal keratinocytes, in
particular to the granular cell layer (Piepkorn et al., 2003;
Rittie et al., 2006). BTC expression is downregulated in
psoriatic skin (Piepkorn et al., 2003). Interestingly, treatment
with retinoids markedly reduced BTC expression in human
skin (Rittie et al., 2006).
In this study, transgenic mice in which BTC is over-
expressed ubiquitously under the control of the cytomegalo-
virus enhancer/chicken b-actin promoter (Schneider et al.,
2005) were employed to study the consequences of excess
BTC in skin and its appendages. Our studies reveal a discrete,
but significant perturbation of cutaneous morphogenesis and
homeostasis, contrasting the more severe effects observed
after overexpression of related growth factors. Interestingly,
however, BTC overexpression retards murine hair follicle
development and cycling, and leads to increased angiogen-
esis at experimental wounding sites.
RESULTS
BTC overexpression produces phenotypical abnormalities in the
skin
During the initial breeding of BTC transgenic mouse line L2
(Schneider et al., 2005), animals displaying wavy hairs were
observed in some litters. This alteration, resembling the
waved phenotype (Luetteke et al., 1993, 1994; Mann et al.,
1993), was particularly evident in young animals (Figure 1a)
and affected exclusively transgenic pups. The phenotype was
easily visible in 10 animals (representing roughly 40% of the
transgenic mice in this generation), and slight alterations
were seen in another five transgenic mice. It remains
unknown why further generations did not display this
phenotype. Although this occasional observation may not
be related to the overexpression of BTC, the known role of
other EGF family members in the skin and its appendages
favored this possibility. Therefore, we carefully examined the
skin of additional litters at different ages. A consistent
retardation in hair coat development in transgenic pups was
detected. This delay was obvious between days 5 and 7 of
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Figure 1. Skin abnormalities in BTC transgenic mice and spatial localization
of the growth factor. (a) Waved hair was observed in some young (less than 4
weeks of age) transgenic animals (indicated by an asterisk) but not in non-
transgenic littermates. (b) Excess of BTC caused a delay in the formation of the
hair coat in transgenic pups (asterisk) as compared to control littermates. The
animals shown here are 6 days old. Immunohistochemistry revealed (c) BTC
expression in the epidermis of control mice and (d) increased levels of BTC in
the epidermis, hair follicles, and sebaceous glands of transgenic littermates.
Bar¼50 mm.
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post-natal life, and was observed in every transgenic mouse
of the litters examined (Figure 1b).
Endogenous and transgene-derived BTC expression in mouse
skin
Although increased BTC expression in the skin of transgenic
mice was detected by western blot during the initial
characterization of the line (data not shown), knowledge of
the site(s) of BTC overexpression within the tissue is essential
for the interpretation of any phenotypical alteration. There-
fore, we employed immunohistochemistry to detect BTC
expression in the tail skin of transgenic mice and their control
littermates. In non-transgenic mice, BTC was localized
almost exclusively in the epidermis (Figure 1c). In the
epidermis of transgenic mice, BTC levels were obviously
increased and BTC was also detected in the hair follicles and
sebaceous glands (Figure 1d).
BTC overexpression enhances keratinocyte proliferation, but
does not affect their differentiation
Histological analysis of the skin of BTC transgenic mice
revealed a slightly increased thickness of the epidermis. We
therefore determined if this phenotype is due to enhanced
proliferation and/or abnormal differentiation of keratinocytes.
Localization of keratin 14 (K14) (marker for basal, prolifera-
tion-competent, non-differentiated keratinocytes), K10
(early differentiation marker), and loricrin (late terminal
differentiation marker) failed to reveal any significant
differences between the skin of transgenic and control
animals (Figure 2a–f). Interfollicular expression of K6 is a
marker for hyperproliferative and/or abnormally differen-
tiated epidermis (Fuchs and Raghavan, 2002; Schweizer
et al., 2006). However, expression of this keratin was
restricted to hair follicles in mice of both genotypes, and no
abnormal expression was detected in interfollicular epidermis
(Figure 2a–f).
Although differentiation abnormalities were not detect-
able, the number of BrdU-positive cells in the epidermis of
transgenic mice appeared to be increased as compared to
control animals (Figure 3a and b). In mice of both genotypes,
proliferating keratinocytes were restricted to the basal layer.
To assess this impression objectively, we measured the
number of BrdU-positive cells per mm basement membrane.
Our results show that keratinocyte proliferation is signifi-
cantly increased in the epidermis of transgenic animals
(Figure 3c). These findings demonstrate that BTC stimulates
proliferation of epidermal keratinocytes but does not affect
their differentiation in vivo.
BTC affects hair follicle morphogenesis and cycling
Next, we examined hair follicle morphogenesis during early
post-natal development. At post-natal day 1 (P1), transgenic
mice displayed a significantly (P¼0.01) reduced number of
follicles at stage 6 as compared to their control littermates,
indicating a retardation of follicle morphogenesis (Figure 4a).
At P10, this difference between transgenic and control mice
had been lost and morphogenesis seemed to have catched up
in the transgenic mice (data not shown). Interestingly, at P17,
that is, when morphogenesis is complete and most back skin
pelage follicles have entered spontaneously into hair follicle
cycling by entry into their first catagen phase (apoptosis-
driven hair follicle involution) (Muller-Rover et al., 2001;
Stenn and Paus, 2001), control hair follicles were in the late
catagen phases or even already in telogen, while almost all
follicles of transgenic mice were still in mid- to late catagen
(Figure 4b). This finding indicates a delay in hair cycle
progression (for the telogen phase P¼ 0.041). Expression of
BTC was also studied by immunohistochemistry at this age
and revealed a similar expression pattern as in adult animals
with visibly increased expression of the growth factor (data
not shown).
Wound healing is not affected in BTC transgenic mice
To determine a possible role of BTC in cutaneous wound
repair, we first analyzed its expression in normal skin and in
full-thickness excisional skin wounds of wild-type mice by
RNase protection assay. As shown in Figure 5a, BTC was
expressed in normal skin and throughout the healing process,
with a slight decline during the phase of granulation tissue
formation (3–7 days after injury). Next, we compared
expression levels of BTC in normal skin and in full-thickness
excisional wounds of transgenic and control animals. In both
a b
c
Co Tg
Co Tg
Co Tg
d
e f
Figure 2. Keratinocyte differentiation is not affected in the epidermis of BTC
transgenic mice. The expression patterns of (a, b) K6 (red), (c, d) K10 (red),
K14 (green), and (e, f) loricrin (red) are similar in transgenic and control
animals. Bar¼ 50 mm.
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situations, the transgene-derived BTC signal (Figure 5a, upper
arrow; for explanation see Materials and Methods) was much
stronger than the endogenous BTC signal (Figure 5a, lower
arrow), confirming the overexpression of the growth factor
in transgenic tissues (Figure 5b). Expression of BTC was
predominantly observed in the hyperthickened wound
epidermis as determined by immunohistochemistry (Figure 5c).
In BTC transgenic mice, the staining intensity in the epidermis
was further enhanced, and BTC protein was also found
throughout the granulation tissue in these animals (Figure 5d).
However, the enhanced levels of BTC did not obviously
affect the wound-healing rate as determined by histological
analysis (Figure 5d and data not shown).
Full-thickness incisional wounds were produced in a
different set of animals. After 5 days, wounds were fully
healed in both groups. The animals were killed at this time
and the negative pressure at which the wounds rupture was
measured. No significant difference in bursting strength was
found in transgenic versus control mice (350740 versus
335741mm Hg, respectively, n¼12 wounds from 3 control
and 12 wounds from 3 transgenic mice).
Increased angiogenesis at the wound site in BTC transgenic
mice
Analysis of Masson trichrome-stained sections suggested the
presence of a more extended vascular network in the
granulation tissue of BTC transgenic mice (data not shown).
To verify this impression, we first performed immunofluore-
scence staining of paraffin sections from day 5 wounds using
an antibody against MECA-32, a marker for endothelial cells.
As seen in Figure 6a–d, an increase in the number of MECA-
32-positive dermal vessels was observed in transgenic mice,
and the vessels appeared enlarged as compared to those in
control animals. Morphometrical analysis of MECA-32-
stained tissue sections (Figure 6e and f) revealed that vessel
size and vessel density were indeed increased in transgenic
mice, although the difference to control animals did not
reach statistical significance (Figure 6g and h). The percen-
tage of the wound area, which was covered by vessels,
however, was significantly increased (P¼0.009) in the
wounds of transgenic animals (Figure 6i).
DISCUSSION
The EGFR family and its ligands play pivotal roles in the
development, homeostasis, and pathology of the skin and its
appendages. We have studied the effects of increased levels
of the peptide growth factor BTC, a ligand of the EGFR, in the
skin of transgenic mice. The main consequences of the BTC
excess detected during the course of our study are (1)
increased keratinocyte proliferation, (2) a discrete and
reversible, but significant delay in hair follicle morphogenesis
and cycling, and (3) enhanced wound healing-associated
angiogenesis. These effects observed in the BTC-overexpres-
sing mice may also give a hint to the function of the
endogenous protein, since there are many examples in the
literature where overexpression or inhibition of a growth
factor in normal or wounded skin generated opposite
phenotypes (Werner and Grose, 2003). One example is
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Figure 4. BTC overexpression causes a delay in hair follicle morphogenesis
as well as retarded catagen progression. (a) At post-natal day 1 (P1),
transgenic mice (n¼ 5) displayed a significantly reduced number of follicles at
stage 6 as compared to their control littermates (n¼5). (b) At the beginning of
the first hair cycle at day 17 (d17), most follicles were at the late catagen
stages or telogen in non-transgenic mice (n¼ 8), while nearly all follicles of
transgenic mice (n¼5) were at the mid- to late catagen phases. cat: catagen;
ana: anagen; graphs show means7SEM; *Po0.05.
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Figure 3. Enhanced keratinocyte proliferation in BTC transgenic mice.
(a, b) Cell proliferation in the epidermis, measured by the number of
BrdU-labeled cells (brown dots), appeared to be increased in the transgenic
group. (c) Quantitative measurements (n¼ 7, animals per group) revealed
a significantly higher number of BrdU-positive cells per mm basement
membrane (BM) in transgenic skin. *Po0.05; graph shows means7SEM.
Bar¼50 mm.
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fibroblast growth factor 7, which caused keratinocyte
hyperproliferation and epidermal hyperthickening when
overexpressed in the skin (Guo et al., 1993) and epidermal
hypoplasia together with reduced keratinocyte proliferation
when inhibited through expression of a dominant-negative
receptor mutant (Werner et al., 1994b). Nevertheless,
functional analysis of endogenous BTC in the skin will
require the analysis of knockout mice.
The increased cell proliferation observed in the epidermal
compartment of BTC-overexpressing mice correlates well
with the site of increased BTC expression in the skin and with
the general mitogenic actions reported for BTC in a variety of
cell types in vitro (Dunbar and Goddard, 2000). EGFR ligands
are known stimulators of keratinocyte proliferation (Coffey
et al., 1987; Cook et al., 1991; Hashimoto et al., 1994; Stoll
et al., 1997; Piepkorn et al., 1998; Shirakata et al., 2000), and
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Figure 5. Expression of BTC in healing skin wounds of wild-type and BTC transgenic mice. (a) A 20mg portion of total cellular RNA from normal skin (skin)
and from full-thickness excisional skin wounds (30minutes to 14 days after injury) was analyzed by RNase protection assay for the presence of BTC and
GAPDH mRNAs. A 20 mg portion of tRNA was used as a negative control. As a size marker, 1,000 c.p.m. of the hybridization probes were loaded in the
lane labeled ‘‘probe.’’ (b) RNase protection assay comparing the levels of transgene-derived BTC mRNA (upper arrow) to the endogenous BTC signal
(lower arrow, slightly lower band) in normal skin and in 5-day-old wounds (5dw). Two different RNA samples from different pools of skin and wound tissue
were analyzed for each time point and genotype. Immunostaining of wound sections revealed a remarkably strong expression of BTC in the hyperproliferative
epithelium (HE) in both (c) control and (d) transgenic animals. (d) In the wound harvested from transgenic mice, BTC expression was even higher in the
HE but also strong in the granulation tissue. D, dermis; E, epidermis; Es, eschar; F, fat; G, granulation tissue; HE, hyperproliferative epithelium; HF, hair
follicle. Bar¼ 100mm.
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overexpression of AREG (Cook et al., 1997, 2004) and
TGF-a (Vassar and Fuchs, 1991; Dominey et al., 1993)
in the epidermis of transgenic mice resulted in markedly
increased cell proliferation and delayed differentiation.
Accordingly, reduced cell proliferation was observed in
the interfollicular epidermis of egfr-knockout mice (Hansen
et al., 1996).
Along the same lines, the mild delay in hair follicle
morphogenesis in BTC transgenic mice is not a surprising
finding. The EGFR is essential for normal hair follicle
formation and function, since reduced activity (Murillas
et al., 1995) or complete elimination (Hansen et al., 1996,
1997) of the receptor resulted in severe architectural and
functional alterations of the follicle. Altered hair follicle
structure is also present in TGF-a-knockout (Luetteke et al.,
1993; Mann et al., 1993) and in TGF-a (Vassar and Fuchs,
1991; Dominey et al., 1993) and EGF transgenic mice (Mak
and Chan, 2003). In fact, in a recent study, EGF was
identified as the major EGFR ligand regulating hair follicle
cycling. According to the model proposed by the authors,
EGF may function as a switch that is turned on and off in the
hair follicles, thereby regulating entry to and exit from the
anagen phase (Mak and Chan, 2003). This is in line with the
perturbation of hair follicle cycling observed in our trans-
genic mice at P17. It is conceivable that the excess of BTC
favors binding of this growth factor versus other ligands to the
EGFR. This may prevent the binding of the stronger
keratinocyte mitogens EGF and TGF-a, thereby delaying hair
follicle morphogenesis/cycling.
The EGFR ligands TGF-a, AREG, and EGF have been
previously overexpressed in the skin of transgenic mice,
resulting in a plethora of phenotypical alterations. While it is
essential to bear in mind the limitations posed by the use of
different mouse strains, different transgene expression levels,
or specific cutaneous cell populations expressing the
transgene, our study provides an opportunity to compare
the actions of these molecules in the dermis and epidermis.
EGF overexpression resulted in an arrest of hair follicle
development at the final stage of morphogenesis and a
transient delay in skin development (Mak and Chan, 2003).
AREG overexpression caused a severe inflammatory and
hyperproliferative, psoriasis-like phenotype already present at
parturition (Cook et al., 1997, 2004). Numerous TGF-a-
overexpressing mouse lines have been generated by different
laboratories during the last 15 years (Vassar and Fuchs, 1991;
Dominey et al., 1993; Jhappan et al., 1994; Shibata et al.,
1997). While each model has its own specific phenotype, the
bottom line can be formulated as follows: excess TGF-a in the
skin causes epidermal thickening and enhances the suscepti-
bility of the epidermis to cancer. This was particularly evident
in studies where the TGF-a-overexpressing mice were treated
with chemical carcinogens (Vassar et al., 1992; Jhappan
et al., 1994; Wang et al., 1994; Shibata et al., 1997) or mated
with other tumorigenesis-prone mouse lines like those
overexpressing v-Fos (Wang et al., 1999) or v-Ha-ras (Wang
et al., 2000) in the epidermis. The lack of hyperplasia,
papillomas, or other neoplastic or metaplastic lesions in the
skin of BTC transgenic mice indicates very different actions of
this growth factor in the skin. This is in agreement with a
previous report showing that BTC transcript levels are barely
detectable in different skin tumors, indicating that this growth
factor has a limited role in keratinocyte transformation
(Kiguchi et al., 1998).
Considering the established role of the EGFR and its
ligands in wound healing and the fact that cell proliferation in
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Figure 6. Angiogenesis is increased at the wound site in BTC transgenic
mice. Paraffin sections of day 5 wounds evaluated by immunofluorescence
staining using an antibody against MECA-32 (red) revealed a more dense
vascular network in the granulation tissue of skin wounds from (b, d)
transgenic mice as compared to (a, c) control animals. Counterstaining
with an antibody against pan-keratin (green) was performed to visualize
the wound epidermis. (e, f) MECA-32-stained sections were used for
morphometrical analysis of angiogenesis (n¼ 12 wounds from 5 wild-type
mice and 9 wounds from 4 transgenic mice). Vessel (g) size and (h) density
values tended to be higher in wounds of transgenic mice. (i) The area covered
by vessels was significantly increased in BTC-overexpressing mice as
compared to non-transgenic littermates. **Po0.01; graphs show
means7SEM. Bars¼ (a, b, e, f) 100mm or (c, d) 50mm.
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the epidermis of BTC transgenic mice was increased, it is
surprising that the dynamics of wound healing and the tensile
strength of healing skin wounds were not altered. It may be
possible that the abundance of other EGFR ligands at the
wound site (Grotendorst et al., 1989) masks an effect of BTC
overexpression. HBEGF appears to be the major EGFR ligand
involved in wound healing: it is present at high levels in
human burn wound fluid (McCarthy et al., 1996) and was
also identified as the principal heparin-binding growth factor
in wound fluid of partial-thickness excisional wounds in pigs
(Marikovsky et al., 1993). HBEGF expression was detected in
the advancing epithelial margin, in islands of regenerating
epithelium within burn wounds, and in eccrine sweat glands
(McCarthy et al., 1996). It is also expressed in hair follicle
epithelial cells and keratinocytes at the wound edge,
particularly during the phase of keratinocyte proliferation
(Cribbs et al., 2002). HBEGF was also shown to be the most
potent EGFR ligand in stimulating wound repair in a porcine
wound model (Okwueze et al., 2007). Finally, in keratino-
cyte-specific HBEGF-deficient mice, the migration, but not
the proliferation, of keratinocytes at the wound site was
impaired (Shirakata et al., 2005).
The increase in angiogenesis at the wound site of BTC
transgenic animals is a remarkable feature that has not been
reported previously for other EGFR ligands. The psoriasis-like
lesions seen in AREG transgenic mice are highly vascular-
ized, but this is an inherent characteristic of the inflammatory
process of the skin in these animals (Cook et al., 1997, 2004)
and may be due to overexpression of VEGF in the
hyperproliferative epidermis. It has been clearly demons-
trated that the EGFR is closely involved in the regulation of
tumor angiogenesis (Bruns et al., 2000; Karashima et al.,
2002). In fact, BTC itself has been implicated in angiogenesis
of head and neck squamous cell carcinoma (Charoenrat
et al., 2000) and of hepatocellular carcinoma (Moon et al.,
2006). Moreover, Kim et al. (2003) demonstrated a strong
angiogenic effect of BTC using human umbilical vein
endothelial cells. These authors have identified activation of
mitogen-activated protein kinase and phosphatidylinositide
30-kinase as the major signaling pathways involved in this
activity (Kim et al., 2003). Thus, increased formation of blood
vessels as a direct effect of BTC is feasible, in particular since
BTC is highly overexpressed in the granulation tissue of our
transgenic animals. However, since many other angiogenic
factors, including IGF, VEGF, and TGF-b1, are abundant in
skin wounds (Werner and Grose, 2003), an indirect effect
cannot be excluded. Independent of its mechanisms of
action, this study provided evidence for a role of BTC in
wound angiogenesis.
While angiogenesis is not rate-limiting during wound
healing in wild-type mice (Bloch et al., 2000), it is a crucial
problem in poorly healing wounds, such as in wounds of
diabetic mice and patients. For example, wound angiogenesis
was shown to be impaired in the genetically diabetic db/db
mouse (Greenhalgh et al., 1990). Topically applied VEGF
reversed this phenotype through increased angiogenesis and
by mobilizing and recruiting bone marrow-derived cells
(Galiano et al., 2004). Therefore, it will be interesting to
determine if BTC has a similar effect in diabetic mice and if it
can improve the healing deficiency in these animals.
Together with the lack of an oncogenic effect of BTC, this
may suggest the use of this growth factor for the treatment of
patients suffering from poorly vascularized ulcers.
MATERIALS AND METHODS
Animals
The generation and routine genotyping of BTC transgenic mice have
been described in detail previously (Schneider et al., 2005). Mice
used in expression studies and for phenotype analysis were weaned
at an age of 3 weeks, and tail tips were used for genotyping by PCR.
For the studies reported here, animals from the line L2 were used.
Only hemizygous animals and their control littermates in an FVB
background were employed. The animals were maintained under
specific pathogen-free conditions in a closed barrier system and had
free access to a standard rodent diet and water. All experimental
procedures were approved by the authors’ (E.W. and S.W.)
institutional committee on animal care and carried out with
permission from the responsible veterinary authority.
Tissue processing, immunohistochemistry, and
immunofluorescence
Tail skin was fixed overnight in 4% paraformaldehyde in phosphate-
buffered saline (for hematoxylin–eosin or Masson trichrome staining)
or 95% ethanol/1% acetic acid (for immunohistochemistry and
immunofluorescence). Immunolocalization of BTC and blood
vessels was carried out with a goat polyclonal anti-BTC antibody
(R&D, Wiesbaden, Germany) or with a rat monoclonal antibody
against MECA-32 (BD Biosciences, San Jose, CA), respectively.
Counterstaining of MECA-32-stained tissues was performed with a
pan-keratin antibody (Abcam, Cambridge, UK). For immunofluore-
scence, ethanol/acetic acid-fixed paraffin sections (6 mm) from tail
skin or wounds were incubated overnight at 41C with the primary
antibodies diluted in phosphate-buffered saline containing 3% BSA
and 0.025% NP-40. After three 10minutes washes with phosphate-
buffered saline/0.1% Tween-20, sections were incubated for 1 hour
with the secondary antibodies, washed again, mounted with Mowiol
(Hoechst, Frankfurt, Germany) and photographed with a Zeiss
Axioplan fluorescence microscope. We used rabbit polyclonal
antibodies against K14, K6, loricrin (BabCO, Richmond, CA), a rat
monoclonal anti-MECA-32 antibody (see above), and a murine
monoclonal anti-K10 antibody (Dako, Hamburg, Germany). Secon-
dary antibodies (coupled to Cy2 or Cy3) were from Jackson
ImmunoResearch (West Grove, PA).
Detection of proliferating cells by labeling with BrdU
Mice were injected intraperitoneally with BrdU (250mg kg1,
Sigma, Buchs, Switzerland, in 1 phosphate-buffered saline) and
killed 2 hours after injection. Skin was fixed in 95% ethanol/1%
acetic acid overnight and embedded in paraffin. Dewaxed 6 mm
sections were rehydrated, incubated with a horseradish peroxidase-
conjugated monoclonal antibody directed against BrdU (Roche,
Mannheim, Germany), and stained using 3,30-diaminobenzidine
substrate (Sigma). Counterstaining was performed with hematoxylin.
The sections were photographed using a Zeiss Axiophot microscope
equipped with an HRC camera (Zeiss, Jena, Germany). A total
of 10–13 pictures per mouse were analyzed. The number of
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BrdU-positive cells was determined using the Openlab 3.1.5
software (Improvision Ltd, Basel, Switzerland) and related to the
length of the basement membrane.
Hair follicle morphogenesis studies
Skin samples obtained from a defined dorsal region were dissected at
the level of the subcutis, fixed in buffered paraformaldehyde (4%),
and embedded in paraffin. Samples were cut parallel to the spine to
obtain longitudinal hair follicle sections. Evaluation of hair follicle
morphogenesis and cycle stage was performed by quantitative
histomorphometry, following widely accepted guidelines (Paus
et al., 1999) as previously described in detail (Nakamura et al.,
2003; Bamberger et al., 2005).
Wounding and preparation of wound tissue
Four full-thickness excisional wounds (5mm diameter each) were
made on either side of the dorsal midline of anesthetized transgenic
and control females by excising skin and panniculus carnosus as
described previously (Werner et al., 1994a). Wounds were left
uncovered and harvested 5 days after injury, bisected, fixed, and
embedded in paraffin as described above. Alternatively, the complete
wound including 2mm of the wound margins was dissected and
immediately frozen in liquid nitrogen for subsequent RNA isolation.
Wound bursting strength
The dorsal region of anesthetized mice was shaved and treated with
a depilatory agent (Pilca Perfect; Stafford-Miller Continental, Oevel,
Belgium). Two full-thickness excisions (1 cm) were made, and the
skin margins were closed with strips of a wound plaster (Fixomull
Stretch; Beiersdorf, Hamburg, Germany). Five days later, mice were
killed and the bursting strength of the wound was determined in situ
using the BTC-2000 system (SRLI Technologies, Nashville, TN),
according to the manufacturer’s instructions.
RNase protection assay
RNA isolation from wound tissue and RNase protection assay was
performed as described previously (Werner et al., 1993). Samples of
20mg total RNA from normal and wounded skin at different stages after
injury were used. Hybridization was performed with a 32P-labeled
antisense riboprobe corresponding to nucleotides 122–362 of the BTC
cDNA (GI 31542237) and additional 12 nucleotides derived from the
original transgene expression vector, which are therefore specific for
the transgene. With this riboprobe, a 253-bp protected fragment is
obtained for the transgene-derived RNA and a 241-bp protected
fragment is obtained for the endogenous mRNA. Hybridization with a
riboprobe corresponding to nucleotides 566–685 of the murine
glyceraldehyde 3-phosphate dehydrogenase cDNA (GAPDH cDNA;
NM_008084) was performed as a loading control.
Statistical analysis
Statistical significance was determined using unpaired student’s
t-tests. Differences were considered significant if Po0.05.
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